The current environment is all about Covid-19 and that will be the all consuming priority in the months ahead....worldwide.  Maxed out hospitals, stressed out care workers, etc., etc.  This has to, presumably, impact any clinical trial initiatives that drug companies plan to undertake, I would think at least for the remainder of 2020. It would seem likely that no one in the healthcare field will have time for anything else.

The obvious question then is, how will that impact RVX?  Do they pivot to being part of a Covid-19 solution in the meantime until everything calms down?  Was that the strategy behind the Covid PRs?  How does this impact partnering discussions that are surely taking place?  How does the company tread water financially given such a delay?

While Covid-19 was an unforeseen event a few short months ago I don't believe it will impact the longer term goal of ABL commercialization.  That said, i would think that it does present significant shorter term challenges.